Rhythm Research Development from 2010 to 2026
| RYTM Stock | USD 96.06 2.41 2.45% |
Research Development | First Reported 2012-12-31 | Previous Quarter 42.3 M | Current Value 46 M | Quarterly Volatility 20.5 M |
Check Rhythm Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rhythm Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 11.9 M or Selling General Administrative of 174.2 M, as well as many indicators such as Price To Sales Ratio of 28.67, Dividend Yield of 9.0E-4 or PTB Ratio of 19.61. Rhythm financial statements analysis is a perfect complement when working with Rhythm Pharmaceuticals Valuation or Volatility modules.
Rhythm | Research Development | Build AI portfolio with Rhythm Stock |
Evaluating Rhythm Pharmaceuticals's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Rhythm Pharmaceuticals's fundamental strength.
Latest Rhythm Pharmaceuticals' Research Development Growth Pattern
Below is the plot of the Research Development of Rhythm Pharmaceuticals over the last few years. It is Rhythm Pharmaceuticals' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rhythm Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Rhythm Research Development Regression Statistics
| Arithmetic Mean | 89,226,566 | |
| Geometric Mean | 45,730,214 | |
| Coefficient Of Variation | 106.44 | |
| Mean Deviation | 74,439,658 | |
| Median | 50,337,000 | |
| Standard Deviation | 94,974,724 | |
| Sample Variance | 9020.2T | |
| Range | 282.1M | |
| R-Value | 0.89 | |
| Mean Square Error | 1999.2T | |
| R-Squared | 0.79 | |
| Slope | 16,740,222 | |
| Total Sum of Squares | 144323.2T |
Rhythm Research Development History
About Rhythm Pharmaceuticals Financial Statements
Rhythm Pharmaceuticals investors utilize fundamental indicators, such as Research Development, to predict how Rhythm Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 273.7 M | 287.3 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Rhythm Pharmaceuticals Correlation against competitors. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Biotechnology sector continue expanding? Could Rhythm diversify its offerings? Factors like these will boost the valuation of Rhythm Pharmaceuticals. Anticipated expansion of Rhythm directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Rhythm Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Rhythm Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rhythm Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Rhythm Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.